Physician profile
Amyn Malik
NPI 1063651156
$4,582.07
in general payments reported to CMS, 2019-2025
38 companies · $872 in 2025
The $872 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.94 · 2020: $197 · 2021: $448 · 2022: $681 · 2023: $710 · 2024: $1,627 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Travel and Lodging: $687 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.23 |
| Travel and Lodging | $687.44 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $794.47 | 2024 | Barostim Neo System |
| Amgen INC. | $425.68 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $419.92 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.75 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $295.70 | 2020-2025 | Verquvo, Belsomra, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $282.98 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.51 | 2020-2024 | Xifaxan, Trulance, Cycloset |
| Abbott Laboratories | $171.76 | 2021-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $148.61 | 2020-2024 | Jardiance, Zepbound, Mounjaro |
| Corcept Therapeutics | $131.70 | 2024-2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $128.97 | 2021-2024 | |
| Pfizer INC. | $122.90 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.86 | 2025 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $115.96 | 2022-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $90.73 | 2022-2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $80.74 | 2022-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $80.07 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $66.07 | 2021-2025 | Farxiga, Breztri |
| Impulse Dynamics (USA) INC. | $56.27 | 2024-2025 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.26 | 2022-2023 | Lifevest |
| Antares Pharma, INC. | $41.30 | 2021-2022 | |
| Lundbeck LLC | $39.91 | 2024 | Vyepti |
| Genentech USA, INC. | $38.94 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $37.39 | 2022 | |
| Abbvie INC. | $32.39 | 2021-2023 | |
| Dexcom, INC. | $23.26 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $22.42 | 2023 | Nexletol |
| Xeris Pharmaceuticals, INC. | $21.52 | 2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $20.92 | 2025 | Licart, Flector, Tirosint |
| Exact Sciences Corporation | $20.10 | 2025 | The Cologuard Plus Collection Kit |
| Horizon Therapeutics Plc | $19.63 | 2022 | |
| Ardelyx, INC. | $19.05 | 2024 | Ibsrela |
| Allergan, INC. | $18.43 | 2020 | |
| Amarin Pharma, INC. | $17.40 | 2022 | |
| Avvisto Therapeutics, LLC | $17.16 | 2024 | Cycloset |
| Biohaven Pharmaceuticals, INC. | $16.69 | 2021 | |
| Althera Pharmaceuticals LLC | $15.38 | 2021 | |
| Axsome Therapeutics, INC. | $15.27 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amyn Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.